- Home
- CNX vs LNTH Comparison
CNX vs LNTH Comparison
Compare CNX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNX
- LNTH
- Stock Information
- Founded
- CNX 1860
- LNTH 1956
- Country
- CNX United States
- LNTH United States
- Employees
- CNX N/A
- LNTH N/A
- Industry
- CNX Oil & Gas Production
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CNX Energy
- LNTH Health Care
- Exchange
- CNX Nasdaq
- LNTH Nasdaq
- Market Cap
- CNX 4.5B
- LNTH 3.8B
- IPO Year
- CNX 1999
- LNTH 2015
- Fundamental
- Price
- CNX $37.03
- LNTH $55.20
- Analyst Decision
- CNX Hold
- LNTH Buy
- Analyst Count
- CNX 11
- LNTH 6
- Target Price
- CNX $33.00
- LNTH $74.17
- AVG Volume (30 Days)
- CNX 2.0M
- LNTH 1.3M
- Earning Date
- CNX 10-30-2025
- LNTH 11-06-2025
- Dividend Yield
- CNX N/A
- LNTH N/A
- EPS Growth
- CNX N/A
- LNTH N/A
- EPS
- CNX 2.02
- LNTH 2.39
- Revenue
- CNX $1,930,542,000.00
- LNTH $1,525,933,000.00
- Revenue This Year
- CNX $44.07
- LNTH N/A
- Revenue Next Year
- CNX $4.49
- LNTH $1.98
- P/E Ratio
- CNX $18.38
- LNTH $22.78
- Revenue Growth
- CNX 40.99
- LNTH 1.95
- 52 Week Low
- CNX $27.00
- LNTH $47.25
- 52 Week High
- CNX $41.93
- LNTH $111.29
- Technical
- Relative Strength Index (RSI)
- CNX 72.21
- LNTH 49.67
- Support Level
- CNX $31.47
- LNTH $50.16
- Resistance Level
- CNX $37.77
- LNTH $61.92
- Average True Range (ATR)
- CNX 1.04
- LNTH 2.65
- MACD
- CNX 0.41
- LNTH -0.43
- Stochastic Oscillator
- CNX 87.81
- LNTH 40.59
About CNX CNX Resources Corporation
CNX Resources Corp is an independent low carbon intensity natural gas and midstream company engaged in the exploration, development, production and acquisition of natural gas properties in the Appalachian Basin. The company's operating segment include Shale and Coalbed Methane. It generates maximum revenue from the Shale segment. It also has other segment that includes nominal shallow oil and gas production.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.